专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09394268B2 (E)-1-(5-methoxy-2,2-dimethyl-2H-chromen-8-yl)-3-(4-methoxyphenyl)prop-2-en-1-one and analogs thereof, as well as preparation method and use thereof 有权
标题翻译：（E）-1-（5-甲氧基-2,2-二甲基-2H-色烯-8-基）-3-（4-甲氧基苯基）丙-2-烯-1-酮及其类似物，以及制备方法和用途
公开(公告)号：US09394268B2
公开(公告)日：2016-07-19
申请号：US14398643
申请日：2012-05-25
申请人： Lijuan Chen , Yuquan Wei
发明人： Lijuan Chen , Yuquan Wei
IPC分类号： C07D413/00 , C07D311/74 , C07D405/06 , C07D407/06 , C07D409/06 , C07D405/10 , C07D405/12 , C07D407/12
CPC分类号： C07D311/74 , C07D405/06 , C07D405/10 , C07D405/12 , C07D407/06 , C07D407/12 , C07D409/06
摘要： The present invention relates to millepachine ((E)-1-(5-methoxy-2,2-dimethyl-2H-chromen-8-yl)-3-(4-methoxyphenyl)prop-2-en-1-one) and its analogs. The present invention provides methods for preparing these compounds, pharmaceutical compositions including these compounds, and methods of treating diseases utilizing pharmaceutical compositions including these compounds.
摘要翻译：本发明涉及二甲基亚胺（（E）-1-（5-甲氧基-2,2-二甲基-2H-色烯-8-基）-3-（4-甲氧基苯基）丙-2-烯-1-酮）及其类似物。本发明提供了制备这些化合物的方法，包括这些化合物的药物组合物，以及使用包括这些化合物的药物组合物治疗疾病的方法。

2. 发明授权

US09096601B2 Arylamino purine derivatives, preparation method and pharmaceutical use thereof 有权
标题翻译：芳基氨基嘌呤衍生物，其制备方法和药物用途
公开(公告)号：US09096601B2
公开(公告)日：2015-08-04
申请号：US13699960
申请日：2010-12-23
申请人： Shengyong Yang , Yuquan Wei
发明人： Shengyong Yang , Yuquan Wei
IPC分类号： C07D473/16 , C07D473/18 , C07D473/32
CPC分类号： C07D473/32 , C07D473/16 , C07D473/18
摘要： Arylamino purine derivatives represented by formula I and their preparation method are disclosed, wherein each substituent is defined as in the description. The derivatives have an inhibitory effect on non-small cell lung cancer with deletion mutation of exon 19 or L858R point mutation of exon 21 in epidermal growth factor receptor (EGFR).
摘要翻译：公开了由式I表示的芳基氨基嘌呤衍生物及其制备方法，其中每个取代基如描述中所定义。该衍生物对表皮生长因子受体（EGFR）中外显子19或外显子21的L858R点突变的缺失突变的非小细胞肺癌具有抑制作用。

3. 发明授权

US08946436B2 Oxazolidinone compounds and their uses in preparation of antibiotics 有权
标题翻译：恶唑烷酮化合物及其在制备抗生素中的应用
公开(公告)号：US08946436B2
公开(公告)日：2015-02-03
申请号：US14126999
申请日：2012-06-15
申请人： Youfu Luo , Zhenling Wang , Yuquan Wei , Funeng Geng
发明人： Youfu Luo , Zhenling Wang , Yuquan Wei , Funeng Geng
IPC分类号： C07D401/00 , C07D413/10 , C07D413/14 , C07D401/04
CPC分类号： C07D413/10 , C07D401/04 , C07D413/14
摘要： The invention belongs to the field of medicaments, and particularly relates to oxazolidinone compounds and their uses in the preparation of antibiotics. A technical problem to be solved by the invention is to provide new oxazolidinone compounds having the structure represented by Formula I. The oxazolidinone compounds of the invention, which are new compounds obtained through numerous screening, have significant antibacterial activity against bacteria such as drug-resistant staphylococcus aureus, fecal coliform bacteria, and streptococcus pneumoniae, while exhibiting low toxicity. The invention provides new options for the development and application of antibiotics.
摘要翻译：本发明属于药物领域，特别涉及恶唑烷酮化合物及其在制备抗生素中的用途。本发明要解决的技术问题是提供具有由式I表示的结构的新的恶唑烷酮化合物。作为通过多次筛选获得的新化合物的本发明的恶唑烷酮化合物对抗细菌如抗药性具有显着的抗菌活性金黄色葡萄球菌，粪大肠菌群和肺炎链球菌，同时表现出低毒性。本发明为抗生素的开发和应用提供了新的选择。

4. 发明申请

US20130203986A1 Arylamino Purine Derivatives, Preparation Method and Pharmaceutical Use Thereof 有权
标题翻译：芳基嘌呤衍生物，其制备方法及药物用途
公开(公告)号：US20130203986A1
公开(公告)日：2013-08-08
申请号：US13699960
申请日：2010-12-23
申请人： Shengyong Yang , Yuquan Wei
发明人： Shengyong Yang , Yuquan Wei
IPC分类号： C07D473/32 , C07D473/16 , C07D473/18
CPC分类号： C07D473/32 , C07D473/16 , C07D473/18
摘要： Arylamino purine derivatives represented by formula I and their preparation method are disclosed, wherein each substituent is defined as in the description. The derivatives have an inhibitory effect on non-small cell lung cancer with deletion mutation of exon 19 or L858R point mutation of exon 21 in epidermal growth factor receptor (EGFR).
摘要翻译：公开了由式I表示的芳基氨基嘌呤衍生物及其制备方法，其中每个取代基如描述中所定义。该衍生物对表皮生长因子受体（EGFR）中外显子19或外显子21的L858R点突变的缺失突变的非小细胞肺癌具有抑制作用。

5. 发明申请

US20140303152A1 BENZOTHIAZINETHIONE DERIVATIVES AND PREPARATION METHODS AND USES THEREOF 审中-公开
标题翻译：苯并噻唑衍生物及其制备方法及用途
公开(公告)号：US20140303152A1
公开(公告)日：2014-10-09
申请号：US14234501
申请日：2011-06-15
申请人： Luoting Yu , Yuquan Wei
发明人： Luoting Yu , Yuquan Wei
IPC分类号： C07D279/08 , C07D417/04 , C07D491/113 , C07D417/12
CPC分类号： C07D279/08 , C07D417/04 , C07D417/12 , C07D491/113
摘要： Benzothiazinethione derivatives of formula (I), their preparative methods and uses are provided. Benzothiazinethione derivatives of the invention have significant effect of inhibiting Mycobacterium tuberculosis.
摘要翻译：提供式（I）的苯并噻嗪硫酮衍生物，其制备方法和用途。本发明的苯并噻嗪硫酮衍生物具有显着的抑制结核分枝杆菌的作用。

6. 发明申请

US20140142144A1 Oxazolidinone Compounds and Their Uses in Preparation of Antibiotics 有权
标题翻译：恶唑烷酮化合物及其在制备抗生素中的用途
公开(公告)号：US20140142144A1
公开(公告)日：2014-05-22
申请号：US14126999
申请日：2012-06-15
申请人： Youfu Luo , Zhenling Wang , Yuquan Wei , Funeng Geng
发明人： Youfu Luo , Zhenling Wang , Yuquan Wei , Funeng Geng
IPC分类号： C07D413/10 , C07D413/14
CPC分类号： C07D413/10 , C07D401/04 , C07D413/14
摘要： The invention belongs to the field of medicaments, and particularly relates to oxazolidinone compounds and their uses in the preparation of antibiotics. A technical problem to be solved by the invention is to provide new oxazolidinone compounds having the structure represented by Formula I. The oxazolidinone compounds of the invention, which are new compounds obtained through numerous screening, have significant antibacterial activity against bacteria such as drug-resistant staphylococcus aureus, fecal coliform bacteria, and streptococcus pneumoniae, while exhibiting low toxicity. The invention provides new options for the development and application of antibiotics.
摘要翻译：本发明属于药物领域，特别涉及恶唑烷酮化合物及其在制备抗生素中的用途。本发明要解决的技术问题是提供具有由式I表示的结构的新的恶唑烷酮化合物。作为通过多次筛选获得的新化合物的本发明的恶唑烷酮化合物对抗细菌如抗药性具有显着的抗菌活性金黄色葡萄球菌，粪大肠菌群和肺炎链球菌，同时表现出低毒性。本发明为抗生素的开发和应用提供了新的选择。

7. 发明申请

US20070275049A1 Anti-tumor molecular vacine and method of making thereof 审中-公开
标题翻译：抗肿瘤分子荧光素及其制备方法
公开(公告)号：US20070275049A1
公开(公告)日：2007-11-29
申请号：US11649155
申请日：2006-12-27
申请人： Yuquan Wei , Ling Tian
发明人： Yuquan Wei , Ling Tian
IPC分类号： A61K39/00 , A61K39/02 , A61K39/12 , A61K39/23 , A61K9/127 , A61K9/14 , C12N5/00 , G01N33/574
CPC分类号： A61K39/0011 , A61K2039/5256 , A61K2039/53
摘要： The present invention provides a vaccine which is capable of inhibiting the growth and formation of tumors which can express an endogenous tumor specific protein. Also disclosed are methods of administering the vaccine to a subject bearing a tumor whose formation and growth is inhibited by the vaccine.
摘要翻译：本发明提供能够抑制可表达内源性肿瘤特异性蛋白质的肿瘤的生长和形成的疫苗。还公开了将疫苗施用于携带其形成和生长被疫苗抑制的肿瘤的受试者的方法。

8. 发明授权

US09290582B2 B cell activating factor antagonist and preparation method and use thereof 有权
标题翻译： B细胞激活因子拮抗剂及其制备方法及用途
公开(公告)号：US09290582B2
公开(公告)日：2016-03-22
申请号：US13699903
申请日：2011-05-26
申请人： Li Yang , Yuquan Wei
发明人： Li Yang , Yuquan Wei
IPC分类号： C07K19/00 , C07K14/47 , C07K14/705 , A61K38/00 , A61K48/00 , A61K31/7088
CPC分类号： C07K19/00 , A61K31/7088 , A61K38/00 , A61K48/005 , C07K14/4703 , C07K14/70578 , C07K2319/00 , C07K2319/30
摘要： The present invention relates to the field of genetic engineering drugs, particularly to a novel B cell activating factor (BAFF) antagonist and use thereof. The technical problem to be solved by the invention is to find a new and effective selection for the prevention and treatment of autoimmune diseases. The B cell activating factor receptor antagonist is mainly obtained by the fusion of the domain 2 binding BAFF in TACI receptor and the domain binding BAFF in Br3 receptor, and it also can be fused with a Fc segment of IgG1 to obtain a new fusion protein molecule. Experiments indicate that said new fusion protein molecule has the function of BAFF antagonist, which can treat the autoimmune diseases, and supply a new and effective selection for the prevention and treatment of the autoimmune diseases.
摘要翻译：本发明涉及遗传工程药物领域，特别涉及一种新型B细胞激活因子（BAFF）拮抗剂及其应用。本发明要解决的技术问题是找到一种新的有效的预防和治疗自身免疫性疾病的选择。 B细胞激活因子受体拮抗剂主要通过融合TACI受体中的结构域2结合BAFF和Br3受体结合BAFF的结构域而获得，并且还可以与IgG1的Fc区融合以获得新的融合蛋白分子。实验表明，所述新型融合蛋白分子具有BAFF拮抗剂的功能，可以治疗自身免疫性疾病，为预防和治疗自身免疫性疾病提供新的有效选择。

9. 发明申请

US20150133659A1 (E)-1-(5-METHOXY-2,2-DIMETHYL-2H-CHROMEN-8-YL)-3-(4-METHOXYPHENYL)PROP-2-EN-1-ONE AND ANALOGS THEREOF, AS WELL AS PREPARATION METHOD AND USE THEREOF 有权
标题翻译：（E）-1-（5-甲氧基-2,2-二甲基-2H-咔唑-8-基）-3-（4-甲氧基苯基）丙-2-烯-1-酮及其类似物，作为制剂方法及其应用
公开(公告)号：US20150133659A1
公开(公告)日：2015-05-14
申请号：US14398643
申请日：2012-05-25
申请人： Lijuan Chen , Yuquan Wei
发明人： Lijuan Chen , Yuquan Wei
IPC分类号： C07D311/74 , C07D405/06 , C07D407/12 , C07D407/06 , C07D405/12 , C07D405/10 , C07D409/06
CPC分类号： C07D311/74 , C07D405/06 , C07D405/10 , C07D405/12 , C07D407/06 , C07D407/12 , C07D409/06
摘要： The present invention relates to millepachine ((E)-1-(5-methoxy-2,2-dimethyl-2H-chromen-8-yl)-3-(4-methoxyphenyl)prop-2-en-1-one) and its analogues. The present invention provides methods for preparing these compounds, pharmaceutical compositions including these compounds, and methods of treating diseases utilizing pharmaceutical compositions including these compounds.
摘要翻译：本发明涉及二甲基亚胺（（E）-1-（5-甲氧基-2,2-二甲基-2H-色烯-8-基）-3-（4-甲氧基苯基）丙-2-烯-1-酮）及其类似物。本发明提供了制备这些化合物的方法，包括这些化合物的药物组合物，以及使用包括这些化合物的药物组合物治疗疾病的方法。

10. 发明申请

US20130089549A1 B CELL ACTIVATING FACTOR ANTAGONIST AND PREPARATION METHOD AND USE THEREOF 有权
标题翻译： B细胞活化因子拮抗剂及其制备方法及其用途
公开(公告)号：US20130089549A1
公开(公告)日：2013-04-11
申请号：US13699903
申请日：2011-05-26
申请人： Li Yang , Yuquan Wei
发明人： Li Yang , Yuquan Wei
IPC分类号： C07K19/00
CPC分类号： C07K19/00 , A61K31/7088 , A61K38/00 , A61K48/005 , C07K14/4703 , C07K14/70578 , C07K2319/00 , C07K2319/30
摘要： The present invention relates to the field of genetic engineering drugs, particularly to a novel B cell activating factor (BAFF) antagonist and use thereof. The technical problem to be solved by the invention is to find a new and effective selection for the prevention and treatment of autoimmune diseases. The B cell activating factor receptor antagonist is mainly obtained by the fusion of the domain 2 binding BAFF in TACI receptor and the domain binding BAFF in Br3 receptor, and it also can be fused with a Fc segment of IgG1 to obtain a new fusion protein molecule. Experiments indicate that said new fusion protein molecule has the function of BAFF antagonist, which can treat the autoimmune diseases, and supply a new and effective selection for the prevention and treatment of the autoimmune diseases.
摘要翻译：本发明涉及遗传工程药物领域，特别涉及一种新型B细胞激活因子（BAFF）拮抗剂及其应用。本发明要解决的技术问题是找到一种新的有效的预防和治疗自身免疫性疾病的选择。 B细胞激活因子受体拮抗剂主要通过融合TACI受体中的结构域2结合BAFF和Br3受体结合BAFF的结构域而获得，并且还可以与IgG1的Fc区融合以获得新的融合蛋白分子。实验表明，所述新型融合蛋白分子具有BAFF拮抗剂的功能，可以治疗自身免疫性疾病，为预防和治疗自身免疫性疾病提供新的有效选择。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式